$SVRA
Savara Inc
Nasdaq · Healthcare · Pharmaceutical Preparations · Austin, TX
SVRA chart
What traders are saying about $SVRA
Latest postsSavara Inc news
- Savara (SVRA) Jumped, But What Is Behind The Fresh Attention?
Simply Wall Street ·
- Savara Opens Up on the Record Deal That Blocked His Music
Mpasho ·
- Savara stock: Savara presents CHEST data before FDA decision for Savara stock
ad-hoc-news.de ·
- Savara, Inc. Estimates – NASDAQ:SVRA
TradingView ·
- Savara Reveals Bad US Record Deal Kept Him From Releasing Music for 10 Months
Ghafla! ·
- Savara: I couldn’t release music for 10 months because I signed a bad record deal
K24 Digital ·
- Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Yahoo Finance ·
- Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?
Yahoo Finance ·
- Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Yahoo Finance ·
- Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside
tikr.com ·
- Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Yahoo Finance ·
- Savara Announces New Employment Inducement Grant
Yahoo Finance ·
Savara Inc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$118.8M | -$95.9M | -$54.7M | -$38.1M |
| Diluted EPS | $-0.53 | $-0.48 | $-0.33 | $-0.25 |
| Total assets (year end) | $253.4M | $212.9M | $177.6M | $139.8M |
| Cash and equivalents (year end) | $33.2M | $15.1M | $26.6M | $52.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Savara Inc
- Ticker
- SVRA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Austin, TX
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1160308
- Former names
- Mast Therapeutics, Inc., ADVENTRX PHARMACEUTICALS INC, BIOKEYS PHARMACEUTICALS INC
Frequently asked questions
What exchange is Savara Inc listed on?
Savara Inc trades on the Nasdaq under the ticker symbol SVRA.
What industry is Savara Inc in?
Savara Inc is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Savara Inc headquartered?
Savara Inc's business address on file with the SEC is in Austin, TX.
When does Savara Inc's fiscal year end?
Savara Inc's fiscal year ends on December 31.
How much revenue did Savara Inc report?
Savara Inc reported $257,000 in revenue for calendar year 2020, according to its SEC filings.